Allakos Inc
NASDAQ:ALLK

Watchlist Manager
Allakos Inc Logo
Allakos Inc
NASDAQ:ALLK
Watchlist
Price: 0.3291 USD -0.06% Market Closed
Market Cap: 29.7m USD

During the last 3 months Allakos Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on Jun 28, 2024 by Radford Harlan Baird , who sold 87.9k USD worth of ALLK shares.

Last Transactions:
Radford Harlan Baird
$-87.9k
Walker Paul Edward
$+3m
Janney Daniel
$+2.4m
James Steven P
$-432.5k
Tomasi Adam
$-1.8m
Tomasi Adam
$-1.8m
Tomasi Adam
$-228.9k
Tomasi Adam
$-57.9k
Alexander Robert
$-1.3m
Rasmussen Henrik S Md
$-218.2k
Alexander Robert
$-1.3m
Alexander Robert
$-1.4m
Alexander Robert
$-1.4m
Alexander Robert
$-1.5m
Alexander Robert
$-1.4m
Tomasi Adam
$-2m
Tomasi Adam
$-2m
Tomasi Adam
$-1.9m
Tomasi Adam
$-2.2m
Tomasi Adam
$-2.1m
Tomasi Adam
$-2.1m
Rasmussen Henrik S Md
$-1.1m
Rasmussen Henrik S Md
$-2.3m
Rasmussen Henrik S Md
$-2.3m
Mckearn John P
$-855.5k
Janney Daniel
$-1.7m
Janney Daniel
$-1.1m
Alexander Robert
$-2.4m
Alexander Robert
$-2.4m
James Steven P
$-425.8k
Alexander Robert
$-2.5m
Janney Daniel
$-835.5k
View All Transactions

During the last 3 months Allakos Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on Jun 28, 2024 by Radford Harlan Baird , who sold 87.9k USD worth of ALLK shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Allakos Inc
Insider Trading Chart

Allakos Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Allakos Inc
Last Insider Transactions

Global
Insiders Monitor

Allakos Inc
Glance View

Market Cap
29.5m USD
Industry
Biotechnology

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Redwood City, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

ALLK Intrinsic Value
0.8942 USD
Undervaluation 63%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top